INTRODUCTION
In this paper, we review the literature regarding the ototoxicity of the antibiotics vancomycin and erythromycin and focus on the evidence for ototoxicity induced by these antibiotics and conclusions drawn from these studies regarding proof of causation and the degree of reversibility.
VANCOMYCIN
Vancomycin is a glycopeptide (55) antibiotic that was originally used extensively to treat infections caused by methicillin-resistant staphylococci. Soon after its initial use, vancomycin was reported to produce ototoxicity. For example, in 1958 Geraci et al. reported a case of one patient who developed slight tinnitus and deafness on day 12 of treatment (21) . The patient's "moderate deafness" persisted until his death from congestive heart failure 2 weeks following termination of vancomycin therapy. In this same article, the authors mentioned another, unreported case, in which tinnitus began on about day 12 of therapy. This patient was reported to have had "complete perceptive type deafness." No mention was made as to whether there was any recovery of hearing. In a subsequent review article in 1977, Geraci mentioned that hearing loss caused by vancomycin is rare and that occasionally the hearing improves when treatment with vancomycin is stopped (20) . It is not clear whether the hearing improvement referred to either one or both of the previous two cases. No additional case reports were noted in that article.
In 1959 Dutton and Elmes reported that five of nine patients experienced a hearing loss while receiving vancomysin therapy (12) . Three of the five were also being treated with streptomycin, and all were also being treated with erythromycin. Because of the known ototoxic effects of erythromycin (46) , especially in patients with renal failure, as was in the case for all five of the patients, it is possible that all of these cases represented hearing loss caused by erythromycin. This possibility is more likely in that the hearing deficit was noted by the patients without the use of audiometric testing. Because erythromycin decreases hearing at all frequencies, including the frequencies used for speech, a symptomatic hearing deficit is to be expected (53) . On the other hand, hearing losses that only affect the high frequencies often go unnoticed unless detected by audiometric testing (33, 41, 42) .
In 1960 Dangerfield et al. found three cases of vancomycin ototoxicity in a study involving 85 patients (9) . One patient had temporary tinnitus only, and one patient treated with vancomycin alone had some change in auditory thresholds * Corresponding author.
that did not resolve. The third patient received vancomycin along with kanamycin, and the onset of the hearing loss began 4 days after discontinuation of vancomycin but while the patient was still on kanamycin.
In 1960 Kirby et al. reported hearing loss in a patient receiving vancomycin therapy (34) . However, the hearing loss started while the patient was receiving neomycin, which was administered just prior to starting the vancomycin. In 1961 Woodley and Hull reported a-case of "moderate nerve deafness" that was discovered 2 months after discontinuation of vancomycin therapy (70) .
In 1971 Morris and Bilinsky reported no ototoxic effects of vancomycin in 25 patients with end-stage renal disease (52) . As much as 54 g of vancomycin was administered to individual patients over a 2-year period.
In a 1977 review article, Esposito and Gleckman mentioned that vancomycin has produced irreparable harm to some patients, including deafness (17) . The data cited for this statement were from a study by Waisbren et al. in 1960 (68) . In that study, only one patient treated with vancomycin had any hearing loss, and this was temporary (68) . Of note is the fact that the patient received only 3 g of vancomycin intravenously over a 2-h time period. Because of tachycardia, dyspnea, elevated temperature, and oliguria from the vancomycin, the therapy was switched to chloramphenicol and erythromycin. Eighteen hours later, the patient complained of difficulty in hearing. The hearing appeared to improve with a twice-daily injection of pyridoxine (50 mg) and was normal at the end of her hospital stay. The role of the pyridoxine is not clear but, because of the known temporary hearing loss caused by erythromycin (46) , especially in oliguric patients, it is possible that this was another case of erythromycin ototoxicity.
In 1978 Cook and Farrar mentioned that ototoxicity remains the most serious complication of vancomycin therapy (8) . This was a review article, and as such no new data were introduced. However, the reference for this statement was an article by Rothenberg (57) , who mentioned in his introduction that vancomycin is ototoxic. Rothenberg listed no references, and in his case report no mention of ototoxicity was made.
In 1978 Hook and Johnson reported that three patients experienced a slight decrease in auditory thresholds at frequencies greater than 4 kHz after 3 to 5 weeks of vancomycin therapy (27) (44) . The first patient complained of tinnitus and vertigo after 11 days of therapy with vancomycin. Both symptoms dissipated after vancomycin was discontinued. The second patient complained of tinnitus, deafness, and vertigo after a total dose of 56 g of vancomycin had been administered at a rate of 1 g two times per day. Again, as with the first patient, the symptoms dissipated 24 h after discontinuation of vancomycin, and at no time did the patient's pre-and postdrug audiograms reveal any hearing loss. This patient was also receiving the aminoglycoside antibiotic amikacin. The third patient had an increased threshold of 20 dB at three frequencies in the left ear and one frequency in the right ear. She was also receiving gentamicin. She was not available for follow-up.
In 1985 Mellor et al. published a prospective study of 34 patients treated with 39 courses of vancomycin therapy (45) . Temporary tinnitus and dizziness with no symptomatic hearing loss were noted in two patients. One patient had a 30-dB change at one frequency in one ear only. No follow-up audiometry was done. The other patient had a 20-dB change in auditory thresholds at 0.25, 0.5, and 4 kHz in the left ear and a 20-dB change at 0.5 kHz in the right ear. This patient was also receiving gentamicin, and no follow-up audiometry was done to see if the changes persisted. These authors did not refer to their 1984 article in this publication, so it is difficult to know if any of these cases were also reported in 1984 (44) .
In 1985 Hall et al. published a report of a 6-month-old female infant who inadvertently received a 10-times overdose of vancomycin (24) . This infant had end-stage renal disease secondary to acute tubular necrosis related to birth asphyxia. At (22) , that some of the originally reported toxic effects resulted from these impurities. The vancomycin in use today is considerably purer than the original product; however, although rare, reports of ototoxicity caused by vancomycin continue to appear in the literature. Nevertheless, in all instances of permanent hearing loss reported to be caused by vancomycin of which we are aware, the patient received an aminoglycoside antibiotic just before, during, or just after the administration of vancomycin. Because ototoxicity caused by an aminoglycoside can begin up to several weeks after therapy has been terminated (19) , it is quite possible that the reported ototoxicity was caused by the aminoglycoside alone or that vancomycin enhanced the ability of the aminoglycoside to produce ototoxicity.
Wood et al. showed that vancomycin enhances aminoglycoside antibiotic nephrotoxicity in rats (69) . The mechanism of the enhanced nephrotoxic effect is not known, but the evidence did not support the hypothesis that an enhanced uptake of aminoglycoside antibiotic resulted from the drug combination. The only report of a similar effect regarding ototoxicity is an abstract by Brummett et al. (R. E. Brummett, F. Jacobs, Z. Stokes, and K. E. Fox, Assoc. Res. Otolaryngol. Midwinter Meeting, 1987, abstr. no. 159, p. 125).
From the above review of the literature, it is obvious that the ototoxic liability of vancomycin itself is in doubt. Because of the small number of cases of vancomycin ototoxicity reported, it is possible that a very small number of cases of true vancomycin ototoxicity have occurred. However, the recent demonstration of its ototoxic interaction with the aminoglycosides and the frequency with which the two have been used in patients reported to have vancomycin-induced ototoxicity may explain the confusion. It is possible that vancomycin is only ototoxic when used with other ototoxic agents, such as aminoglycosides.
ERYTHROMYCIN
Erythromycin is a macrolide antibiotic that was discovered in 1952 in the metabolic products of a strain of Streptomyces erythreus. It is widely used in clinical medicine and is generally considered to be a very safe antibiotic. Despite its widespread use the ototoxic effect of erythromycin was not reported until 1973 by Mintz et al. (51) . There may be several reasons for the long delay in discovering that erythromycin is ototoxic. The first is that the chemical structure of erythromycin is not similar to that of any other drug known to be ototoxic. Therefore, because of the low index of suspicion, if any patient developed a hearing loss while receiving erythromycin, the erythromycin would not be a prime suspect for its cause. The second is that it was not until 1973 that erythromycin was being used in such large dosages, such as 1 g every 6 h, which now appear necessary to induce a hearing loss.
The second report of erythromycin ototoxicity was not until 1975 by Eckman et al. (14) . As with the two patients reported by Mintz et al. (51) , the ototoxicity in this case report of a single patient resulted from the administration of rather large doses, was noticed first by the patient, and was apparently reversible. Unfortunately, there were no predrug audiograms for comparison. However, the patient's hearing was reported to improve subjectively after cessation of erythromycin therapy. Neither this patient nor the two previous patients reported tinnitus or vertigo. It did not appear as if any single route of administration or erythromycin preparation was involved, since both patients reported by Mintz et al. (51) had received erythromycin lactobionate intravenously and the patient described by Eckman et al. (14) had received erythromycin stearate orally.
The first audiograms of patients suffering erythromycininduced hearing loss were published in 1977 by Karmody and Weinstein (32) . Three case reports were described, and it was felt by the authors that the hearing loss was reversible in all three patients. However, for only one patient was a predrug audiogram obtained. This patient had been treated with streptomycin previously and had an audiogram on 30 December 1969 that demonstrated a high-frequency hearing loss. On 5 February 1970 (48 h after initiation of erythromycin therapy) the patient complained of a loss of hearing, and an audiogram revealed a 50-to 60-dB hearing loss at all frequencies. It was reported that over the next 48 h hearing gradually returned to predrug threshold values. However, the last audiogram reported on 9 February 1970 still revealed a 10-to 20-dB loss from the base-line audiogram. The changes were more severe at the speech frequencies than at the high frequencies. No predrug audiograms were obtained for the other two patients. Both had an improvement of 15 to 20 dB in their thresholds after termination of erythromycin therapy, but they still had hearing losses that were slightly worse than those of age-matched controls (43) . Only one patient complained of tinnitus.
Quinnan and McCabe reported two cases of reversible hearing loss following the intravenous administration of erythromycin lactobionate (56) . One patient complained of tinnitus and vertigo, which disappeared after therapy. Again, no audiograms were published. vanMarion et al. reported two cases of reversible hearing loss following the oral administration of erythromycin stearate (67) . Again, there were no predrug audiograms to document recovery.
Three reports of transient hearing loss were published in 1979 (31, 39, 46) . However, in none of these reports were there predrug audiograms with which to compare audiometrically confirmed drug-induced hearing losses for the completion of recovery. Four similar papers appeared in 1980 (16, 30, 48, 64 (63) . One patient had double vision along with the hearing loss. The double vision persisted until the day after the antibiotics were withdrawn, and the hearing returned to normal (no predrug audiograms) within a few days. The second patient was reported to have slurred speech and was also very confused at the time he was found to have a hearing loss. The deafness, slurred speech, and confusion resolved completely over 3 days (again, no predrug audiograms). Both of these patients were on peritoneal dialysis, but the diplopia, slurred speech, and confusion were believed to have been drug related by the authors, suggesting that erythromycin may have had some generalized central nervous system effects. In 1981 Cohen and Weitz (7) also described two case reports of psychiatric complications believed to be caused by erythromycin. The first was a 4-year-old male who was taking erythromycin ethylcarbonate for an upper respiratory tract infection. The symptoms occurred again 9 months later when he was treated with erythromycin again. The second was a 45-year-old male who was being treated with erythromycin ethyl stearate on two separate occasions, and both times he complained of "confusion, fear, lack of control, abnormal thinking and a feeling of impending unconsciousness or being drugged." No alteration in hearing was reported for either patient. Also, in 1981 Errick and Hyrciuk-Flaska reported a mild reversible sensorineural hearing loss that was most pronounced in the high frequencies (15) . This case was complicated by the fact that the patient was given amikacin during the same time period.
Schwartz and Maggini reported a case of reversible hearing loss in a patient following the intravenous administration of erythromycin gluceptate (59) . The principal complication during the first course of therapy was the onset of "marked bilateral deafness, which began 1 day after the patient began receiving" the drug "and resolved within 2 days following completion of therapy" (4.5 weeks). No audiograms were obtained. About 7 months later another course of erythromycin gluceptate was initiated, and the patient complained of a hearing loss 24 h later. Speech reception thresholds were 74 and 76 dB in the right and left ears, respectively, at that time. After the hearing returned the patient still had speech reception thresholds of 24 dB on the right and 22 dB on the left. These were considered to represent a reversible hearing VOL. 33, 1989 on October 19, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHE; loss, although no predrug audiograms were obtained to document complete recovery.
In 1982 Miller reported the follow-up audiograms of a patient who suffered a 60-to 70-dB hearing deficit following erythromycin therapy (50) . Over the following month some hearing returned, with a 20-to 30-dB loss at frequencies up to 4 kHz and then a gradual slope to 55 dB at 8 kHz. This would not be an unexpected threshold for a 71-year-old female, but to assume that hearing had returned to its original level is only speculative.
Kroboth et al. reported a very unusual case of a 52-year-old male who developed a hearing loss after receiving five 1-g doses of erythromycin lactobionate every 6 h (36). At that time the patient was unable to hear conversational tones and complained of "blowing" tinnitus. There was no vertigo. Only one more dose was given, and 2 days later the patient's hearing had subjectively improved, but audiometric examinations revealed speech reception thresholds of 44 dB on the right and 52 dB on the left. Tympanograms and acoustic reflexes were reported to be within normal limits. However, 3 weeks later repeat audiometric examinations revealed marked improvement, with speech reception thresholds of 14 dB on the right and 12 dB on the left, but the acoustic reflex was now abnormal on the left. The nature of this abnormality was not reported. All other drugs that the patient received during the hospitalization were listed, but none are known to be ototoxic. In 1983 Mery and Kanfer issued a warning of the hearing loss caused by high-dose erythromycin in patients with Legionnaires disease (47) .
In 1984 five reports of erythromycin-induced hearing loss were published. Rydberg (58) and Demaldent et al. (11) reported one patient each who experienced a reversible hearing loss following erythromycin therapy. In addition, in 1984 Haydon et al. reported two cases of reversible erythromycin-induced hearing loss, and in one case an audiogram was obtained 5 days before the erythromycin therapy was started (26) . This audiogram revealed bone conduction thresholds of 0, 10, and 0 dB at 0.25, 0.5, and 1 kHz, respectively, with a marked high-frequency hearing loss presumably induced by tobramycin. During the erythromycin therapy the bone conduction thresholds at the three respective frequencies fell to 30, 25, and 40 dB. At 133 days posterythromycin therapy they were still 10, 20, and 20 dB, respectively. It is not clear whether these data represent a progression of the tobramycin ototoxicity, test-retest measurement error, or permanent changes induced by erythromycin.
Schweitzer and Olson reported a case of reversible ototoxicity associated with intravenously administered erythromycin lactobionate (60) . The hearing loss was confirmed audiometrically, and the speech reception thresholds were 45 dB bilaterally. A repeat audiogram 14 months later demonstrated a persistent 20-dB speech reception threshold and high-tone losses at 4 and 8 kHz bilaterally. A 50-year-old female might be expected to have some high-frequency hearing deficit, but there was no evidence that her hearing returned to predrug levels.
Hugues et al. reported that 30 patients treated orally with relatively low dosages of erythromycin stearate (1.5 to 2 g/day) for 11 days did not show any change between auditory thresholds obtained before and at the end of the treatment period (28) , suggesting that erythromycin-induced hearing losses either occur very rarely or require higher doses closer to 4 g per day, as are sometimes used. One case of erythromycin-induced hearing loss was reported in 1985 (35 (49) . In 1988 Dylewski (13) reported a case of persistent hearing loss in a 73-year-old female treated with erythromycin lactobionate (500 mg intravenously every 6 h). She was receiving no other drugs and was treated for pneumonia, but the organism involved was not identified.
There are only two animal experiments demonstrating the ototoxic activity of erythromycin. The first, by Stupp et al. in 1973, reported that many drugs, including erythromycin, applied to the middle ear space resulted in an almost complete loss of cochlear hair cells (62) . However, because of the unusual route of administration it is not clear how these data relate to ototoxicity resulting from erythromycin administered by more usual routes. If erythromycin is capable of causing hair cell death, the result would be permanent hearing loss, since mammalian cochlear hair cells cannot regenerate. Brummett 36, p. 25) reported that when erythromycin was infused intravenously in anesthetized guinea pigs at a rate of 125 mg/kg per h, the initial effect was an increase in the latency of the fourth peak of the auditory brain stem evoked response. The fourth peak eventually disappeared. These effects were subsequently followed by similar changes in the third and finally the second waves. When drug administration was discontinued, all changed values returned to control values. No changes were found in the alternating current cochlear potential or compound action potential thresholds. It has not been reported if similar changes occur in humans. However, if the central nervous system does represent the site of the ototoxic effect of erythromycin, it would suggest that there is some drug-induced change in the central nervous system that results in the ototoxic effect. This suggestion would be consistent with the reports of central nervous system changes in patients receiving erythromycin therapy (7, 63, 66) .
The bulk of the evidence for erythromycin-induced ototoxicity indicates that it is a reversible effect which occurs at high doses, such as 1 g every 6 h, or in patients with hepatic and/or renal abnormalities. The fact that some case reports have described general central nervous system effects at ototoxic doses of erythromycin and the demonstration in animals that the site of action is in the central auditory pathways suggest that these pathways may also be the site of action in humans.
